Muparfostat ' Analysis and Market Forecasts from 2017 to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Muparfostat ' Analysis and Market Forecasts from 2017 to 2020
Published on October 2011

Report Summary


Summary

GlobalData's pharmaceuticals report, 'Muparfostat ' Analysis and Market Forecasts from 2017 to 2020' provides Muparfostat sales
estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales,
competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes
information on Liver Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases,
primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases,
both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry
experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Muparfostat including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Muparfostat including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2017-2020 for Muparfostat in the seven major markets
-

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4

Muparfostat ' Analysis and Market Forecasts from 2017 to 2020 (From Slideshare) Page 1/5


2.1 Liver Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 5
2.3.1 Hepatitis B Infection 5
2.3.2 Hepatitis C Infection 5
2.3.3 Alcohol 5
2.3.4 Aflatoxin B1 6
2.3.5 Hemochromatosis 6
2.3.6 Diabetes and Obesity 6
2.3.7 Cirrhosis 6
2.4 GlobalData Report Guidance 6
3 Liver Cancer : Market Characterization 7
3.1 Liver Cancer Market 7
3.2 Liver Cancer Market Forecasts and CAGR 7
3.3 Drivers for the Liver Cancer Market 7
3.3.1 High Incidence 8
3.3.2 High Mortality 8
3.3.3 Large Unmet Need 9
4 Tumor'Node'Metastases (TNM) Classification of Liver Cancer 10
5 Muparfostat 11
5.1 Introduction 11
5.2 Mechanism of Action 11
5.3 Clinical Studies 11
5.4 Approval of Muparfostat 11
5.5 Factors Affecting Sales of Muparfostat 11
5.5.1 Only Drug to be Used in Post Liver Resection Adjuvant Settings 11
5.5.2 Large Increase in Survival Time 11
5.6 Drug Risk Benefit Score 12
5.6.1 Efficacy 12
5.6.2 Safety 12
5.6.3 Compliance 12
5.6.4 Dosing Convenience 12
5.7 Intensity of Competition 12
5.8 Sales Forecast 13
5.8.1 Target Patient Pool of Muparfostat 13
5.8.2 Dosing 13
5.8.3 Market Penetration 13
5.8.4 Annual Cost of Therapy 14
5.8.5 Sales Projections of Muparfostat 15
6 Liver Cancer Market: Appendix 24
6.1 Market Definitions 24
6.2 List of Abberiviations 24
6.3 Research Methodology 24
6.3.1 Coverage 24
6.3.2 Secondary Research 24
6.3.3 Forecasting 25
6.3.4 Number of Patients Approved to take the Drug 25
6.3.5 Net Penetration of Drug 26



6.3.6 Net Annual Dosing 27
6.3.7 Annual Cost of Therapy 27
6.3.8 Primary Research 27
6.3.9 Expert Panels 27
6.4 Drug Sales Estimates Model 27
6.5 Contact Us 28
6.6 Disclaimer 28
6.7 Sources 28

1.1 List of Tables

Table 1: Liver Cancer, Incidences and Mortality, 2008'2030 4
Table 2: Drug Risk Benefit Score (DRB)-Muparfostat 12
Table 3: Annual Cost of Therapy 14
Table 4: Muparfostat, Liver Cancer, Global, Estimated Sales ($m), 2017'2020 15
Table 5: Muparfostat, Liver Cancer, The US, Estimated Sales ($m), 2017'2020 16
Table 6: Muparfostat, Liver Cancer, The UK, Estimated Sales ($m), 2017'2020 17
Table 7: Muparfostat, Liver Cancer, France, Estimated Sales ($m), 2017'2020 18
Table 8: Muparfostat, Liver Cancer, Germany, Estimated Sales ($m), 2017'2020 19
Table 9: Muparfostat, Liver Cancer, Italy, Estimated Sales ($m), 2017'2020 20
Table 10: Muparfostat, Liver Cancer, Spain, Estimated Sales ($m), 2017'2020 21
Table 11: Muparfostat, Liver Cancer, Japan, Estimated Sales ($m), 2017'2020 22

1.2 List of Figures

Figure 1: Fatality = [(% Distribution of Incidence) ' (% Distribution of Mortality)] of Most Common Cancers 5
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 2010'2020 7
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 2008'2030 8
Figure 4: Oncology, Worldwide, Incidence (in millions), 2008'2030 8
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 2008'2030 9
Figure 6: Classification of Liver Cancer 10
Figure 7: Drug Model Diagram of Muparfostat 13
Figure 8: Muparfostat, Liver Cancer, Global, Estimated Sales ($m), 2017'2020 15
Figure 9: Muparfostat, Liver Cancer, The US, Estimated Sales ($m), 2017'2020 16
Figure 10: Muparfostat, Liver Cancer, The UK, Estimated Sales ($m) , 2017'' 2020 17
Figure 11: Muparfostat, Liver Cancer, France, Estimated Sales ($m), 2017'2020 18
Figure 12: Muparfostat, Liver Cancer, Germany, Estimated Sales ($m) , 2017'2020 19
Figure 13: Muparfostat, Liver Cancer, Italy, Estimated Sales ($m), 2017''2020 20
Figure 14: Muparfostat, Liver Cancer, Spain, Estimated Sales ($m),2017'2020 21
Figure 15: Muparfostat, Liver Cancer, Japan, Estimated Sales ($m), 2017'2020 22
Figure 16: Muparfostat, Liver Cancer, Global, Sales Distribution (%), 2020 23
Figure 17: Drug Model Diagram 26
Figure 18: Patients Approved for the Drug 26


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Muparfostat ' Analysis and Market Forecasts from 2017 to 2020

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (8)

More from ReportLinker.com

More from ReportLinker.com (20)

Muparfostat ' Analysis and Market Forecasts from 2017 to 2020